The flesh-eating bacterium: What's next?

Journal of Infectious Diseases

Volumn 179, Issue SUPPL. 2, 1999, Pages

  Stevens, Dennis L ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; EXOTOXIN; PENICILLIN DERIVATIVE; VIRULENCE FACTOR;

ANTIBIOTIC THERAPY; BACTEREMIA; CLINICAL FEATURE; CONFERENCE PAPER; DRUG EFFICACY; HOST RESISTANCE; HUMAN; INFECTION COMPLICATION; MYOSITIS; NECROTIZING FASCIITIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; TOXIC SHOCK SYNDROME;

EID: 4244092996     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513851     Document Type: Conference Paper

References (96)

1. 1. Stevens DL, Tanner MH, Winship J, et al. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: severe group A streptococcal infections associated with a toxic shock-like syndrome. N Engl J Med 1989; 321:1-7.
2. 2. Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome: rationale and consensus definition. JAMA 1993; 269:390-1.
3. 3. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med 1996; 335:547-54.
4. 4. Cockerill FR, MacDonald KL, Thompson RL, et al. An outbreak of invasive group A streptococcal disease associated with high carriage rates of the invasive clone among school-aged children. JAMA 1997; 277: 38-43.
5. 5. Sennert D. De febribus libri quator. Editio novissima. Cui accessit fasciculus medicamentorum contra pestem. Libri IV. De peste, Pestilentibusque ac Malingis Febribus. Venice: Francisum Baba, 1641.
6. 6. Douglass W. The practical history of a new epidemical eruptive miliary fever, with an Angina Ulcusculosa, which prevailed in Boston, New England in the years 1735 and 1736. Boston: T. Fleet, 1736.
7. 7. Wannamaker LW, Rammelkamp CH Jr, Denny FW, et al. Prophylaxis of acute rheumatic fever by treatment of the preceding streptococcal infection with various amounts of depot penicillin. Am J Med 1951; 10:673-95.
8. 8. Dillon HC. Impetigo contagiosa: suppurative and nonsuppurative complication. Clinical, bacteriologic and epidemiologic characteristics of impetigo. Am J Dis Child 1968; 115:530-41.
9. 9. Weaver GH. Scarlet fever. In: Abt IA, ed. Pediatrics. Philadelphia: WB Saunders, 1925:298-362.
10. 10. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14:2-13.
11. 11. Kohler W, Gerlach D, Knoll H. Streptococcal outbreaks and erythrogenic toxin type A. Zentralbl Bakteriol Mikrobiol Hyg 1987; 266:104-15.
12. 12. Martin PR, Hoiby EA. Streptococcal serogroup A epidemic in Norway 1987-1988. Scand J Infect Dis 1990; 22:421-9.
13. 13. Holm SE. Invasive group A streptococcal infections. N Engl J Med 1996; 335:590-1.
14. 14. Wheeler MC, Roe MH, Kaplan EL, Schlievert PM, Todd JK. Outbreak of group A streptococcus septicemia in children. Clinical, epidemiologic, and microbiological correlates. JAMA 1991; 266:533-7.
15. 15. Gaworzewska ET, Coleman G. Group A streptococcal infections and a toxic shock - like syndrome [letter]. N Engl J Med 1989; 321:1546.
16. 16. Schwartz B, Facklam RR, Brieman RF. Changing epidemiology of group A streptococcal infection in the USA. Lancet 1990; 336:1167-71.
17. 17. Bartter T, Dascal A, Carroll K, Curley FJ. "Toxic strep syndrome": manifestation of group A streptococcal infection. Arch Intern Med 1988; 148:1421-4.
18. 18. Hribalova V. Streptococcus pyogenes and the toxic shock syndrome. Ann Intern Med 1988; 108:772.
19. 19. Greenberg RN, Willoughby BG, Kennedy DJ, Otto TJ, McMillian R, Bloomster TG. Hypocalcemia and "toxic" syndrome associated with streptococcal fasciitis. South Med J 1983; 76:916-8.
20. 20. Jackson MA, Olson LC, Burry VF. Pediatric group A streptococcal (GAS) disease with multi-organ dysfunction [abstract 652]. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (Atlanta). Washington, DC: American Society for Microbiology, 1990.
21. 21. Thomas JC, Carr SJ, Fujioka K, Waterman SH. Community-acquired group A streptococcal deaths in Los Angeles County. J Infect Dis 1989; 160:1086-7.
22. 22. Kiska DL, Thiede B, Caracciolo J, et al. Invasive group A streptococcal infections in North Carolina: epidemiology, clinical features, and genetic and serotype analysis of causative organisms. J Infect Dis 1997; 176:992-1000.
23. 23. Francis J, Warren RE. Streptococcus pyogenes bacteraemia in Cambridge - a review of 67 episodes. Q J Med 1988; 256:603-13.
24. 24. Bamham M. Invasive streptococcal infections in the era before the acquired immune deficiency syndrome: a 10 years' compilation of patients with streptococcal bacteraemia in North Yorkshire. J Infect 1989; 18:231-48.
25. 25. Braunstein H. Characteristics of group A streptococcal bacteremia in patients at the San Bernardino County Medical Center. Rev Infect Dis 1991; 13:8-11.
26. 26. Gray ED. Purification and properties of an extracellular blastogen produced by group A streptococci. J Exp Med 1979; 149:1438-49.
27. 27. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992; 166:31-7.
28. 28. Stegmayr B, Bjorck S, Holm S, Nisell J, Rydvall A, Settergren B. Septic shock induced by group A streptococcal infections: clinical and therapeutic aspects. Scand J Infect Dis 1992; 24:589-97.
29. 29. Demers B, Simor AE, Vellend H, et al. Severe invasive group A streptococcal infections in Ontario, Canada: 1987-1991. Clin Infect Dis 1993; 16:792-800.
30. 30. Auerbach SB, Schwartz B, Facklam RR, Breiman R, Jarvis WR. Outbreak of invasive group A streptococcal (GAS) disease in a nursing home [abstract 508]. In: Program and abstracts of the 30th Interscience Conference on Antimicrobial Agents and Chemotherapy (Atlanta). Washington, DC: American Society for Microbiology, 1990.
31. 31. Hohenboken JJ, Anderson F, Kaplan EL. Invasive group A streptococcal (GAS) serotype M-1 outbreak in a long-term care facility (LTCF) with mortality [abstract J189]. In: Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy (Orlando, FL). Washington, DC: American Society for Microbiology, 1994.
32. 32. Dipersio JR, File TM, Stevens DL, Gardner WG, Petropoulos G, Dinsa K. Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers. Clin Infect Dis 1996; 22:490-5.
33. 33. Gamba MA, Martinelli M, Schaad HJ, et al. Familial transmission of a serious disease-producing group A streptococcus clone: case reports and review. Clin Infect Dis 1997; 24:1118-21.
34. 34. Johnson DR, Stevens DL, Kaplan EL. Epidemiologic analysis of group A streptococcal serotypes associated with severe systemic infections, rheumatic fever, or uncomplicated pharyngitis. J Infect Dis 1992; 166: 374-82.
35. 35. Belani K, Schlievert PM, Kaplan EL, Ferrieri P. Association of exotoxin-producing group A streptococci and severe disease in children. Pediatr Infect Dis J 1991; 10:351-4.
36. 36. Hauser AR, Stevens DL, Kapian EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 1991; 29:1562-7.
37. 37. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci USA 1991; 88:2668-72.
38. 38. Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR. A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest 1993; 92:710-9.
39. 39. Iwasaki M, Igarashi H, Hinuma Y, Yutsudo T. Cloning, characterization, and overexpression of a Streptococcus pyogenes gene encoding a new type of mitogenic factor. FEBS Lett 1993; 331:187-92.
40. 40. Norrby-Teglund A, Newton D, Kotb M, Holm SE, Norgren M. Superantigenic properties of the group A streptococcal exotoxin SpeF (MF). Infect Immun 1994; 62:5227-33.
41. 41. Meleney FL. Hemolytic streptococcus gangrene. Arch Surg 1924; 9:317-64.
42. 42. Adams EM, Gudmundsson S, Yocum DE, Haselby RC, Craig WA, Sundstrom WR. Streptococcal myositis. Arch Intern Med 1985; 145:1020-3.
43. 43. Svane S. Peracute spontaneous streptococcal myositis. A report on 2 fatal cases with review of literature. Acta Chir Scand 1971; 137:155-63.
44. 44. Yoder EL, Mendez J, Khatib R. Spontaneous gangrenous myositis induced by Streptococcus pyogenes: case report and review of the literature. Rev Infect Dis 1987; 9:382-5.
45. 45. Nather A, Wong FY, Balasubramaniam P, Pang M. Streptococcal necrotizing myositis - a rare entity: a report of two cases. Clin Orthop 1987; 215:206-11.
46. 46. Stevens DL, Musher DM, Watson DA, et al. Spontaneous, nontraumatic gangrene due to Clostridium septicum. Rev Infect Dis 1990; 12:286-96.
47. 47. Bullowa JGM, Wishik SM. Complications of varicella I. Their occurrence among 2,534 patients. Am J Dis Child 1935; 49:923-6.
48. 48. Fast DJ, Schlievert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989; 57:291-4.
49. 49. Hackett SP, Schlievert PM, Stevens DL. Cytokine production by human mononuclear cells in response to streptococcal exotoxins [abstract]. Clin Res 1991; 39:189A.
50. 50. Hallas G. The production of pyrogenic exotoxins by group A streptococci. J Hyg (Camb) 1985; 95:47-57.
51. 51. Lancefield RC. Current knowledge of type specific M antigens of group A streptococci. J Immunol 1962; 89:307-13.
52. 52. Mollick JA, Rich RR. Characterization of a superantigen from a pathogenic strain of Streptococcus pyogenes [abstract]. Clin Res 1991; 39:213A.
53. 53. Hackett SP, Stevens DL. Streptococcal toxic shock syndrome: synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O. J Infect Dis 1992; 165:879-85.
54. 54. Kotb M, Tomai M, Majumdar G, Walker J, Beachey EH. Cellular and biochemical responses of human T lymphocytes stimulated with strepto-coccal M protein [abstract L77]. In: XI Lancefield International Symposium on Streptococcal Diseases (Sienna, Italy). Stuttgart, Germany: Gustav Fischer Verlag, 1990.
55. 55. Watanabe-Ohnishi R, Low DE, McGeer A, et al. Selective depletion of Vβ-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. J Infect Dis 1995; 171:74-84.
56. 56. Stevens DL, Bryant AE, Hackett SP. Gram-positive shock. Curr Opin Infect Dis 1992; 5:355-63.
57. 57. Hackett S, Ferretti J, Stevens D. Cytokine induction by viable group A streptococci: suppression by streptolysin O [abstract B-249]. In: Proceedings of the 94th annual meeting of the American Society for Microbiology (Las Vegas). Washington, DC: ASM, 1994.
58. 58. Muller-Alouf H, Alouf JE, Gerlach D, Ozegowski JH, Fitting C, Cavaillon JM. Comparative study of cytokine release by human peripheral blood mononuclear cells stimulated with Streptococcus pyogenes superantigenic erythrogenic toxins, heat-killed streptococci, and lipopolysaccharide. Infect Immun 1994; 62:4915-21.
59. 59. Hackett SP, Stevens DL. Superantigens associated with staphylococcal and streptococcal toxic shock syndromes are potent inducers of tumor necrosis factor-β synthesis. J Infect Dis 1993; 168:232-5.
60. 60. Kappur V, Majesky MW, Li LL, Black RA, Musser JM. Cleavage of interleukin 1β (IL-1β) precursor to produce active IL-1β by a conserved extracellular cysteine protease from Streptococcus pyogenes. Proc Natl Acad Sci USA 1993, 90:7676-80.
61. 61. Cleary P, Chen C, Lapenta D, Bormann N, Heath D, Haanes E. A virulence regulon in Streptococcus pyogenes [abstract 19]. In: Program and abstracts of 3rd International ASM Conference on Streptococcal Genetics (Minneapolis). Washington, DC: American Society for Microbiology, 1990.
62. 62. Cleary PP, Kaplan EL, Handley JP, et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 1992; 339: 518-21.
63. 63. Nida SK, Ferretti JJ. Phage influence on the synthesis of extracellular toxins in group A streptococci. Infect Immun 1982; 36:745-50.
64. 64. Johnson LP, Tomai MA, Schlievert PM. Bacteriophage involvement in group A streptococcal pyrogenic exotoxin A production. J Bacteriol 1986; 166:623-7.
65. 65. Stevens DL. Invasive group A streptococcal infections: the past, present, and future. Pediatr Infect Dis J 1994; 13:561-6.
66. 66. Kim KS, Kaplan EL. Association of penicillin tolerance with failure to eradicate group A streptococci from patients with pharyngitis. J Pediatr 1985; 107:681-4.
67. 67. Gatanaduy AS, Kaplan EL, Huwe BB, McKay C, Wannamaker LW. Failure of penicillin to eradicate group A streptococci during an outbreak of pharyngitis. Lancet 1980; 2:498-502.
68. 68. Brook I. Role of beta-lactamase-producing bacteria in the failure of penicillin to eradicate group A streptococci. Pediatr Infect Dis 1985; 4:491-5.
69. 69. Kohler W. Streptococcal toxic shock syndrome. Zentralbl Bakteriol 1990; 272:257-64.
70. 70. Eagle H. Experimental approach to the problem of treatment failure with penicillin. I. Group A streptococcal infection in mice. Am J Med 1952; 13:389-99.
71. 71. Stevens DL, Bryant-Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis 1988; 158:23-8.
72. 72. Stevens DL, Bryant AE, Yan S. Invasive group A streptococcal infection: new concepts in antibiotic treatment. Int J Antimicrob Agents 1994; 4: 297-301.
73. 73. Stevens DL, Yan S, Bryant AE. Penicillin binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. J Infect Dis 1993; 167: 1401-5.
74. 74. Yan S, Mendelman PM, Stevens DL. The in vitro antibacterial activity of ceftriaxone against Streptococcus pyogenes is unrelated to penicillin-binding protein 4. FEMS Microbiol Lett 1993; 110:313-8.
75. 75. Yan S, Bohach GA, Stevens DL. Persistent acylation of high-molecular-weight penicillin binding proteins by penicillin induces the postantibiotic effect in Streptococcus pyogenes. J Infect Dis 1994; 170:609-14.
76. 76. Stevens DL, Maier KA, Mitten JE. Effect of antibiotics on toxin production and viability of Clostridium perfringens. Antimicrob Agents Chemother 1987; 31:213-8.
77. 77. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest 1981; 67:1249-56.
78. 78. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis 1995; 20(suppl): S154-7.
79. 79. Stevens DL, Hackett SP, Bryant AE. Suppression of mononuclear cell synthesis of tumor necrosis factor by azithromycin [abstract 181]. In: Proceedings of the 33rd annual meeting of the Infectious Disease Society of America (San Francisco). Alexandria, VA: IDSA, 1997.
80. 80. Yong JM. necrotizing fasciitis [letter]. Lancet 1994; 343:1427.
81. 81. Norrby-Teglund A, Kaul R, Low DE, McGeer A, Kotb M. Intravenous immunoglobulin and superantigen-neutralizing activity in streptococcal toxic shock syndrome patients [abstract LM67]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
82. 82. Barry W, Hudgins L, Donta S, Pesanti E. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 1992; 267:3315-6.
83. 83. Mahieu LD, Holm SE, Goossens HJ, Van Acker KJ. Congenital streptococcal toxic shock syndrome with absence of antibodies against streptococcal pyrogenic exotoxins. J Pediatr 1995; 127:987-9.
84. 84. Chieu CH, Lin TY. Successful treatment of severe streptococcal toxic shock syndrome with a combination of intravenous immunoglobulin, dexamethasone, and antibiotics. Infection 1997; 25:47-8.
85. 85. Nadal D, Lauener RP, Braegger CP, et al. T cell activation and cytokine release in streptococcal toxic shock - like syndrome. J Pediatr 1993; 122: 727-9.
86. 86. Lamothe F, D'Amico P, Ghosn P, Tremblay C, Braidy J, Patenaude JV. Clinical usefulness of intravenous human immunoglobulins in invasive group A streptococcal infections: case report and review. Clin Infect Dis 1995; 21:1469-70.
87. 87. Perez CM, Kubak BM, Cryer HG, Salehmugodam S, Vespa P, Farmer D. Adjunctive treatment of streptococcal toxic shock syndrome using intravenous immunoglobulin: case report and review. Am J Med 1997; 102:111-3.
88. 88. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Low DE, Ontario Streptococcal Study Group. Intravenous immunoglobulin (IVIG) therapy in streptococcal toxic shock syndrome (STSS): results of a matched case-control study [abstract LM68]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington, DC: American Society for Microbiology, 1995.
89. 89. Norrby-Teglund A, Kaul R, Low DE. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 1996; 156:3057-64.
90. 90. Norrby-Teglund A, Kaul R, Low DE, et al. Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 1996; 64:5395-8.
91. 91. Norrby-Teglund A, Basma H, Andersson J, McGeer A, Low DE, Kotb M. Varying titres of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G (IVIG): implications for therapeutic efficacy. Clin Infect Dis 1998; 26:631-8.
92. 92. Kehoe MA, Kapur V, Whatmore AM, Musser JM. Horizontal gene transfer among A streptococci: implications for pathogenesis and epidemiology. Trends Microbiol 1996; 4:436-43.
93. 93. Greenberg LJ, Gray ED, Yunis E. Association of HL-A5 and immune responsiveness in vitro to streptococcal antigens. J Exp Med 1975; 141: 934-43.
94. 94. Weinstein L, Barza MA. Gas gangrene. N Engl J Med 1973; 289:1129-1131.
95. 95. Zabriskie JB, Lavenchy D, Williams RC Jr, et al. Rheumatic-fever associated B-cell alloantigens as identified by monoclonal antibodies. Arthritis Rheum 1985; 28:1047-51.
96. 96. Schwartz B, Elliot JA, Butler JC, et al. Clusters of invasive group A streptococcal infections in family, hospital, and nursing home settings. Clin Infect Dis 1992; 15:277-84.